Short-term and long-term survival of patients with gastric cancer
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. 2 (2021),
8 March 2021
,
Page 115-122
https://doi.org/10.22037/ghfbb.v14i2.1927
Abstract
Aim: The aim of this study was to apply the Bayesian mixture cure rate frailty model to determine the factors that influence short-term and long-term survival of patients with gastric cancer
Background: Determining the risk factors of gastric cancer is currently considered very important, because the disease has become one of the most dangerous types of mortal cancers. Therefore, it is possible to determine the effective risk factors of short-term and long-term survival in patients through utilizing this model.
Methods: The present retrospective study was conducted on 339 gastric cancer patients whose data was recorded in hospitals of Kerman province, Iran, during 2001-2015. In the study, the Bayesian mixture cure rate frailty model was used to determine the effective factors of short-term and long-term survival in patients.
Results: In the present study, the event of interest occurred for 57.5% of patients. Over time, the survival rate of cancer patients reached its lowest point, approximately 0.3 at the end of study. According to the results of the present study, variables of chemotherapy (β=-0.35 (-0.75, -0.03) and OR=1.59 (1.08, 2.19)), morphology (β =-0.98(-1.45, -0.48) and OR=2.99 (1.78, 4.17)), and metastasis (β =0.42(0.10, 0.93) and OR=0.39(0.01, 0.84)) were identified as effective factors in short-term and long-term survival of patients.
Conclusion: The effective factors of long-term and short-term survival can be identified by utilizing the Bayesian mixture cure rate frailty model, while it is impossible through conventional models of survival analysis. Chemotherapy, morphology, and metastasis are the most important effective factors of short-term and long-term survival in patients with gastric cancer.
Keywords: Gastric cancer, Short-term survival, Long-term survival, Cure rate frailty model, Bayesian inference.
(Please cite as: Karamoozian A, Baneshi MR, Bahrampour A. Short-term and long-term survival of patients with gastric cancer. Gastroenterol Hepatol Bed Bench 2021;14(2):115-122).
- Gastric cancer
- short-term survival
- long-term survival
- cure rate model
- frailty
- Bayesian inference
How to Cite
References
Kim S, Chen M-H, Dey DK, Gamerman D. Bayesian dynamic models for survival data with a cure fraction. Lifetime Data Anal 2007;13:17–35.
Othus M, Barlogie B, LeBlanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res 2012;18:3731–6.
Cancho VG, de Castro M, Rodrigues J. A Bayesian analysis of the Conway–Maxwell–Poisson cure rate model. Stat Pap 2012;53:165–76.
Hoseini M, Bahrampour A, Mirzaee M. Comparison of weibull and lognormal cure models with cox in the survival analysis of breast cancer patients in Rafsanjan. J Res Heal Sci 2017;17:1–6.
Wienke A, Lichtenstein P, Yashin AI. A bivariate frailty model with a cure fraction for modeling familial correlations in diseases. Biometrics 2003;59:1178–83.
Martinez EZ, Achcar JA, Jácome AAA, Santos JS. Mixture and non-mixture cure fraction models based on the generalized modified Weibull distribution with an application to gastric cancer data. Comput Methods Programs Biomed 2013;112:343–55.
Lambert PC, Thompson JR, Weston CL, Dickman PW. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 2007;8:576–94.
Chen M-H, Ibrahim JG, Sinha D. Bayesian inference for multivariate survival data with a cure fraction. J Multivar Anal 2002;80:101–26.
Nikaeen R, Khalilian A, Bahrampour A. Determining the effective factors on gastric cancer using frailty model in South-East and North of Iran. Iran J Heal Sci 2017;5:35–48.
Yin G. Bayesian cure rate frailty models with application to a root canal therapy study. Biometrics 2005;61:552–8.
De Souza D, Cancho VG, Rodrigues J, Balakrishnan N. Bayesian cure rate models induced by frailty in survival analysis. Stat Methods Med Res 2017;26:2011–28.
Castro M de, Cancho VG, Rodrigues J. A Bayesian long‐term survival model parametrized in the cured fraction. Biometrical J J Math Methods Biosci 2009;51:443–55.
Seltman H, Greenhouse J, Wasserman L. Bayesian model selection: analysis of a survival model with a surviving fraction. Stat Med 2001;20:1681–91.
Cowles MK, Carlin BP. Markov chain Monte Carlo convergence diagnostics: a comparative review. J Am Stat Assoc 1996;91:883–904.
Cancho VG, Rodrigues J, de Castro M. A flexible model for survival data with a cure rate: a Bayesian approach. J Appl Stat 2011;38:57–70.
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol WJG 2006;12:354–62.
Roder DM. The epidemiology of gastric cancer. Gastric cancer 2002;5:5–11.
Ito Y, Nakayama T, Tsukuma H, Miyashiro I, Ioka A, Sugimoto T, et al. Role of age and tumour stage in the temporal pattern of “cure” from stomach cancer: A population-based study in Osaka, Japan. Cancer Epidemiol 2012;36:128–32.
Yin G, Ibrahim JG. A general class of Bayesian survival models with zero and nonzero cure fractions. Biometrics 2005;61:403–12.
Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol WJG 2006;12:204–13.
Ikoma N, Agnes A, Chen H-C, Wang X, Blum MM, Das P, et al. Linitis Plastica: a Distinct Type of Gastric Cancer. J Gastrointest Surg 2020;24:1018–25.
Khorfan R, Schlick CJR, Yang AD, Odell DD, Bentrem DJ, Merkow RP. Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. J Gastrointest Surg 2020;24:243–52.
DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643–53.
Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27–39.
Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer 2006;106:1624–33.
Yoshikawa K, Kitaoka H. Bone metastasis of gastric cancer. Jpn J Surg 1983;13:173–6.
Li Q, Lv M, Jiang H, Wang Y, Yu S, Li W, et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol 2020;146:287–95.
Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–61.
- Abstract Viewed: 63 times
- PDF Downloaded: 39 times